Parker D C, Greiner D L, Phillips N E, Appel M C, Steele A W, Durie F H, Noelle R J, Mordes J P, Rossini A A
Department of Molecular Genetics and Microbiology, University of Massachusetts Medical School, Worcester 01655, USA.
Proc Natl Acad Sci U S A. 1995 Oct 10;92(21):9560-4. doi: 10.1073/pnas.92.21.9560.
Combined treatment with allogeneic small lymphocytes or T-depleted small lymphocytes plus a blocking antibody to CD40 ligand (CD40L) permitted indefinite pancreatic islet allograft survival in 37 of 40 recipients that differed from islet donors at major and minor histocompatibility loci. The effect of the allogeneic small lymphocytes was donor antigen-specific. Neither treatment alone was as effective as combined treatment, although anti-CD40L by itself allowed indefinite islet allograft survival in 40% of recipients. Our interpretation is that small lymphocytes expressing donor antigens in the absence of appropriate costimulatory signals are tolerogenic for alloreactive host cells. Anti-CD40L antibody may prevent host T cells from inducing costimulatory signals in donor lymphocytes or islet grafts.
在40名与胰岛供体在主要和次要组织相容性位点存在差异的受体中,37名受体接受了同种异体小淋巴细胞或去除T细胞的小淋巴细胞与抗CD40配体(CD40L)阻断抗体的联合治疗,实现了胰岛移植的长期存活。同种异体小淋巴细胞的作用具有供体抗原特异性。单独使用任何一种治疗方法都不如联合治疗有效,尽管单独使用抗CD40L可使40%的受体实现胰岛移植的长期存活。我们的解释是,在缺乏适当共刺激信号的情况下表达供体抗原的小淋巴细胞对同种异体反应性宿主细胞具有耐受性。抗CD40L抗体可能会阻止宿主T细胞在供体淋巴细胞或胰岛移植物中诱导共刺激信号。